Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.
2.

Detection of methamphetamine neurotoxicity in forensic autopsy cases.

Kitamura O.

Leg Med (Tokyo). 2009 Apr;11 Suppl 1:S63-5. doi: 10.1016/j.legalmed.2009.01.003. Epub 2009 Mar 6. Review.

PMID:
19269222
3.

Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.

Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA.

Life Sci. 2003 Jun 27;73(6):727-39. Review.

PMID:
12801594
4.

[New perspectives on the mechanism of methamphetamine-induced neurotoxicity].

Kita T, Takeshima M, Wagner GC, Hozumi H, Miyazaki I, Asanuma M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 Apr;28(2):49-61. Review. Japanese.

PMID:
18516983
5.

The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.

Volz TJ, Hanson GR, Fleckenstein AE.

J Neurochem. 2007 May;101(4):883-8. Epub 2007 Jan 23. Review.

6.

Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption.

Kita T, Wagner GC, Nakashima T.

J Pharmacol Sci. 2003 Jul;92(3):178-95. Review.

7.

Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.

Volz TJ, Fleckenstein AE, Hanson GR.

Addiction. 2007 Apr;102 Suppl 1:44-8. Review.

PMID:
17493052
8.

A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.

Dwoskin LP, Crooks PA.

Biochem Pharmacol. 2002 Jan 15;63(2):89-98. Review.

PMID:
11841781
9.

Impact of psychostimulants on vesicular monoamine transporter function.

Fleckenstein AE, Hanson GR.

Eur J Pharmacol. 2003 Oct 31;479(1-3):283-9. Review.

PMID:
14612158
10.

The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP.

Adv Pharmacol. 2014;69:71-106. doi: 10.1016/B978-0-12-420118-7.00002-0. Review.

11.

Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Fleckenstein AE, Volz TJ, Hanson GR.

Neuropharmacology. 2009;56 Suppl 1:133-8. doi: 10.1016/j.neuropharm.2008.07.002. Epub 2008 Jul 10. Review.

12.

Is there a role for nitric oxide in methamphetamine-induced dopamine terminal degeneration?

Friend DM, Fricks-Gleason AN, Keefe KA.

Neurotox Res. 2014 Feb;25(2):153-60. doi: 10.1007/s12640-013-9415-2. Epub 2013 Aug 6. Review.

13.

Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Crooks PA, Zheng G, Vartak AP, Culver JP, Zheng F, Horton DB, Dwoskin LP.

Curr Top Med Chem. 2011;11(9):1103-27. Review.

14.

Plasma membrane monoamine transporters: structure, regulation and function.

Torres GE, Gainetdinov RR, Caron MG.

Nat Rev Neurosci. 2003 Jan;4(1):13-25. Review. No abstract available.

PMID:
12511858
15.

Pharmacogenetics of monoamine transporters.

Glatt CE, Reus VI.

Pharmacogenomics. 2003 Sep;4(5):583-96. Review.

PMID:
12943466
16.

The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases.

Yulug B, Hanoglu L, Kilic E.

Med Chem. 2015;11(2):104-8. Review.

PMID:
25256242
17.

Catecholamine metabolism: an update on key biosynthetic enzymes and vesicular monoamine transporters.

Flatmark T, Almas B, Ziegler MG.

Ann N Y Acad Sci. 2002 Oct;971:69-75. Review.

PMID:
12438092
18.

Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders.

McAllister TW, Summerall L.

Curr Psychiatry Rep. 2003 Oct;5(5):400-9. Review.

PMID:
13678562

Supplemental Content

Support Center